Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 7:07 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 721–744 of 901 matching trials from the live ClinicalTrials.gov search.
Recruiting No phase listed Observational Accepts healthy volunteers

The Treatment in Pregnancy for Hepatitis C ("TiP-HepC") Registry

NCT05368974
Conditions
Hepatitis C
Interventions
Direct Acting Antivirals
Drug
Lead sponsor
The Task Force for Global Health
Other
Eligibility
Not listed
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Atlanta, Georgia
Conditions
Hepatitis C
Interventions
Elbasvir / Grazoprevir Oral Tablet [Zepatier]
Drug
Lead sponsor
San Francisco Veterans Affairs Medical Center
Federal
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
2
States / cities
San Francisco, California
Conditions
Kidney Transplant, Hepatitis C
Interventions
Direct acting Anti-Viral Therapy using Epclusa or Zepatier
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 80 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Richmond, Virginia
Conditions
Heart Failure
Interventions
Anakinra
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
21 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Richmond, Virginia
Conditions
Hepatitis C, HIV Infections
Interventions
Peer Mentoring Intervention for HCV-Infected IDUs
Behavioral
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 35 Years
Enrollment
750 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
3
States / cities
Baltimore, Maryland • New York, New York • Seattle, Washington
Conditions
Hepatitis C, Chronic
Interventions
BI201335, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
6
States / cities
San Francisco, California • Baltimore, Maryland • New York, New York + 1 more
Conditions
Chronic Hepatitis C Infection
Interventions
Fuzheng Huayu, Placebo
Drug
Lead sponsor
Tarek Hassanein
Individual
Eligibility
18 Years to 70 Years
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
8
States / cities
Coronado, California • Palo Alto, California • Pasadena, California + 5 more
Conditions
Chronic Hepatitis C Virus Infection
Interventions
CTS-1027, Placebo
Drug · Other
Lead sponsor
Conatus Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
19
States / cities
Birmingham, Alabama • La Jolla, California • San Diego, California + 15 more
Conditions
Hepatitis C
Interventions
HCV Assay
Diagnostic Test
Lead sponsor
Beckman Coulter, Inc.
Industry
Eligibility
18 Years and older
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Duluth, Georgia
Conditions
Hepatitis C, Liver Diseases
Interventions
Patient portal message
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
54 Years to 74 Years
Enrollment
1,600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Palo Alto, California
Conditions
Hepatitis C, HIV
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 99 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Hepatitis C, Chronic
Interventions
Sofosbuvir, RBV, PEG
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
332 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
44
States / cities
Montgomery, Alabama • Jonesboro, Arkansas • Anaheim, California + 36 more
Conditions
Hepatitis C
Interventions
ABT-072, placebo
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2008
U.S. locations
1
States / cities
Abbott Park, Illinois
Completed Not applicable Interventional

Fluvastatin Versus Hepatitis C Virus

NCT00441493
Conditions
Hepatitis C
Interventions
fluvastatin
Drug
Lead sponsor
Bader, Ted, M.D.
Individual
Eligibility
18 Years to 75 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Conditions
Chronic Hepatitis C Infection
Interventions
Ombitasvir/paritaprevir/ritonavir, Dasabuvir, Ribavirin, Ombitasvir mini tablet, Paritaprevir mini tablet, Ritonavir mini tablet, Dasabuvir mini tablet, Ribavirin solution
Drug
Lead sponsor
AbbVie
Industry
Eligibility
3 Years to 17 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
11
States / cities
San Francisco, California • Aurora, Colorado • Gainesville, Florida + 7 more
Conditions
Hepatitis C
Interventions
Motivational Interviewing, Single - MIS, Motivational Interviewing Group, Usual Care Group - UCG
Behavioral · Other
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 55 Years
Enrollment
219 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
3
States / cities
Los Angeles, California
Conditions
Hepatitis, Hepatitis C
Interventions
Filibuvir, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
288 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
30
States / cities
Anaheim, California • Coronado, California • La Jolla, California + 22 more
Conditions
Hepatitis C, Chronic
Interventions
ribavirin, Locteron™ (controlled-release interferon alpha 2b), PEG-Intron™
Drug
Lead sponsor
Biolex Therapeutics, Inc.
Industry
Eligibility
18 Years to 69 Years
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
13
States / cities
Chula Vista, California • Oceanside, California • San Diego, California + 10 more
Conditions
Hepatitis C, Chronic
Interventions
Copegus, Pegasys, RO4588161
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 65 Years
Enrollment
516 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
30
States / cities
Phoenix, Arizona • La Jolla, California • Long Beach, California + 26 more
Conditions
Hepatitis C
Interventions
Nudge
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
7,634 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Hepatitis C
Interventions
BI201335, PegIFN/RBV, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 70 Years
Enrollment
658 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
78
States / cities
Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 58 more
Conditions
Hepatitis C
Interventions
Cohort 1 (GSK2336805 60mg x 1 dose, Omeprazole 40 mg q24h x 4 days, GSK2336805 60 mg x 1 dose and Omeprazole 40 mg x 1 dose), Cohort 2 (GSK2336805 30mg x 1 dose, Ritonavir 100mg q12h x 4 days, and Ritonavir 100mg q12h x 1 dose)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Buffalo, New York
Completed Not applicable Interventional Results available

HCV Seek, Test and Rapid Treatment for Young PWID

NCT03627546
Conditions
Hepatitis C, Drug Use
Interventions
Rapid Treatment strategy, Usual Care (facilitated referral)
Other
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 29 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
New York, New York
Conditions
Hepatitis C, Chronic
Interventions
GSK2336805, Pegylated interferon alfa-2a, Ribavirin, GSK2336805 Matching Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 70 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
9
States / cities
Anaheim, California • Chula Vista, California • Coronado, California + 6 more